Cortexin
Cortexin (Neuropeptide Complex)
Russian neuropeptide complex used clinically for decades
Cortexin is a mixture of neuropeptides derived from animal cerebral cortex. Clinically approved in Russia for stroke recovery, cognitive disorders, and neuroprotection.
Admin routes
Intramuscular, Intranasal
Popularity
Niche
Side effects
Monitor closely
AU vendors
0 rated
✓Key benefits
📈What to expect
Improved cognitive clarity; reduced brain fog
Enhanced memory and concentration
Full neuroprotective course completed
Repeat course for sustained benefits
Based on community reports and published research. Individual results vary significantly.
💊Dosing protocols
Cognitive support (IM)
10 mg
Once daily
10-day courses, repeated 2–4 times per year
Intranasal
1 mg per spray, 3 sprays daily
Three times daily
2-week cycles
Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.
Research status|Approved in Russia - limited Western clinical data
Overview
Cortexin is a complex mixture of low-molecular-weight neuropeptides, amino acids, and minerals extracted from the cerebral cortex of young cattle or pigs. It has been clinically approved in Russia and several CIS countries since the 1990s for treating cognitive disorders, stroke recovery, traumatic brain injury, and epilepsy. It is one of the most prescribed neuroprotective agents in Russian clinical medicine.
⚙️How it works
Targets multiple neurological pathways simultaneously: binds glutamatergic and GABAergic receptors (AMPA, kainate, mGluR1/5, GABA-A), inhibits caspase-8 (preventing apoptosis during excitotoxicity), enhances GABA and serotonin neurotransmission, provides antioxidant effects, and stimulates axonal and dendritic growth through neurotrophic factor expression.
⚡Side effects
📅Research history
Developed by Geropharm in St. Petersburg, Russia
Approved for clinical use in Russia
Widely prescribed for stroke, TBI, and cognitive disorders in CIS countries
Published clinical data exceeds 10,000 patients
Growing availability through international peptide suppliers
Russian clinical experience
Cortexin has been used clinically in Russia since the 1990s with over 10,000 patients in published studies. Russian clinical data supports its use for ischaemic stroke recovery, cognitive impairment, and paediatric neurological conditions. However, these studies generally do not meet Western randomised controlled trial standards, and cortexin has not been evaluated by the FDA or TGA.
References
- [1]Shabanov PD, et al. 'Neuroprotective properties of cortexin: experimental and clinical studies.' Medical Academic Journal, 2016.
- [2]Gusev EI, Skvortsova VI. 'Brain ischemia.' Kluwer Academic Publishers, 2003.
Frequently asked questions
Related peptides
Need to calculate your dose?
Use our free reconstitution calculator to work out syringe units for Cortexin.
Open CalculatorDisclaimer: This guide is for educational and informational purposes only. It is not medical advice. The dosing protocols listed are sourced from published research and community reports and do not constitute a recommendation. Always consult a qualified healthcare professional before using any peptide. Australian regulations classify many peptides as Schedule 4 (prescription-only) substances. Check current TGA guidelines before purchasing.